The VEGF (Vascular Endothelial Growth Factor) Trap is a composite decoy receptor fusion protein that contains portions of the extracellular domains of two different VEGF receptors VEGFR-1 (flt-1) and VEGFR-2 (KDR). The VEGF Trap (R1R2) has a high affinity for VEGF. 

In September 2003, Aventis and Regeneron Pharmaceuticals initiated a global agreement (excluding Japan) according to which the companies will together develop and commercialize VEGF Trap. This is a deal with a value of more than 500M USD. Is the actual value of the early stage candidate in this magnitude? BioSeeker Group assesses VEGF Trap and gives you an independent and unbiased valuation.  

BioSeeker believes that an independent, unbiased valuation of an interesting therapeutic candidate is of immense value in the process of choosing different licensing, benchmarking or collaboration projects. All BioSeeker Groups valuations are based on six fundamental aspects of the process in which an invention is developed into a therapeutic reality: 

Scientific Background

IP Situation

R&D Progress

Competitive Landscape

Collaboration Strength

Company Structure

Descriptions of all the six above-mentioned aspects are included. In this way the report provides a general description, structure and analysis of the field as well as a specific valuation of VEGF Trap. The progress in utilizing biological strategies to inhibit vascular endothelial growth factor receptor (VEGF/VEGFR) signal transduction for the treatment of cancer is described. Additionally, small molecular inhibitor candidates of the VEGFR tyrosine kinase are presented.  

In this specific valuation we have chosen to closely study a biological drug with anti-angiogenetic property, utilizing a relative new approach of targeting VEGF. Regeneron's VEGF Trap has been studied in detail and this report reviews this the possibilities and opportunities of this candidate as well as the competition and drawbacks for targeting the VEGF/VEGFR signal transduction pathway. BioSeeker Group has identified a total of 114 different therapies developed utilizing an antiangiogenetic or vascular targeting strategy. The progress of 22 different therapeutic candidates that have a VEGF/VEGFR signal transduction inhibitory effect are also described. For your convenience, data is summarized in tables and graphs to enhance the overall view of this field.

Size: 57 pages

Release date: Jan 27, 2004 

Publisher: BioSeeker 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/BioSeeker.html#a410